<DOC>
	<DOCNO>NCT00220272</DOCNO>
	<brief_summary>- The primary objective study effect SR57667B dose 4 mg/d progression dopaminergic nigro-striatal lesion assess 18F-Dopa PET imaging . - Secondary objective assess effect SR57667B symptomatic decline patient early PD , assess safety/tolerability SR57667B patient early PD document plasma concentration SR57667 patient early PD .</brief_summary>
	<brief_title>Study Effect SR57667B 18F-Dopa PET Imaging Patients With Parkinson 's Disease</brief_title>
	<detailed_description>Multinational , multicenter , randomize , parallel-group , double-blind , phase II study.Randomization stratify dopaminergic treatment , two stratum : treatment levodopa dopamine agonist .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Male female outpatient . Age &gt; =35 year screen . Diagnosis Parkinson 's syndrome , least two three key Parkinson 's symptom , i.e . rest tremor , bradykinesia rigidity . Duration disease less 3 year since diagnosis . Modified Hoehn Yahr stage &lt; = 2.5 . Patient optimize monotherapy levodopa dopamine agonist· Generally healthy ambulatory . Patient give inform write consent capable follow study procedure . Any indication form parkinsonism PD . Severe rest tremor . Presence either dyskinesia , fluctuation , loss postural reflexes· Treatment amantadine , anticholinergic , catecholomethyltransferase ( COMT ) inhibitor , selegiline , dopamine receptor antagonist , catecholamine depleters , indirect dopamine agonist alphamethyldopa . Electroconvulsive therapy ( ECT ) .Use CYP3A4 strong , moderate inducer inhibitor . Participation another clinical trial investigational drug within two month prior randomization . Dementia , uncontrolled depression , psychotic disorder . History substancerelated disorder include alcohol substance use disorder . Females child bear potential . Evidence ( detected history , physical examination and/or laboratory/ECG test ) clinically significant unstable medical disorder could interfere patient 's participation clinical trial ; interfere absorption , metabolism excretion study medication ; interfere evaluation study drug . Alterations laboratory test ECG finding potential clinical significance .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>5-fluorodopa</keyword>
</DOC>